Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 6:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 1,436 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Level B Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants

NCT06027437
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Danicamtiv
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Oct 29, 2026, 6:39 PM EDT
Not listed Not applicable Interventional

Intuitive Control of a Hybrid Prosthetic Leg During Ambulation

NCT04038151
View directory record Official record
Conditions
Amputation
Interventions
Hybrid Leg, Prescribed Passive Prosthesis
Device
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years to 95 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 17, 2024 · Synced Oct 29, 2026, 6:39 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma

NCT01155583
View directory record Official record
Conditions
Refractory Multiple Myeloma
Interventions
azacitidine, lenalidomide, dexamethasone, DNA methylation analysis, gene expression analysis, bone marrow aspiration, immunohistochemistry staining method, reverse transcriptase-polymerase chain reaction, flow cytometry
Drug · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Oct 29, 2026, 6:39 PM EDT
Completed Phase 1 Interventional

Ganitumab and Gemcitabine Hydrochloride Followed by Radiation Therapy, Ganitumab, Capecitabine, and Maintenance Therapy in Treating Patients With Locally Advanced Cancer of the Pancreas

NCT01298401
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
ganitumab, capecitabine, gemcitabine hydrochloride, 3-dimensional conformal radiation therapy
Biological · Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
10
States / cities
Orange, California • Newark, Delaware • Louisville, Kentucky + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Oct 29, 2026, 6:39 PM EDT
Completed Not applicable Interventional

Home COPD and Open Ventilation Evaluation (HOPE) Study

NCT03691181
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Ventilation
Device
Lead sponsor
Landon Pediatric Foundation
Other
Eligibility
40 Years to 100 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Oct 3, 2018 · Synced Oct 29, 2026, 6:39 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

NCT05669430
View directory record Official record
Conditions
Solid Tumor, Adult, Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma, pMMR/MSS Adenocarcinoma of the Colon or Rectum, Cutaneous Melanoma, Non-Small Cell Lung Cancer
Interventions
GV20-0251, GV20-0251 and Pembrolizumab [KEYTRUDA®]
Biological
Lead sponsor
GV20 Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
13
States / cities
Los Angeles, California • Denver, Colorado • New Haven, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Oct 29, 2026, 6:39 PM EDT
Terminated Not applicable Interventional

Step Down Colon Cancer Risk

NCT01476631
View directory record Official record
Conditions
Adenomatous Polyps
Interventions
Walking
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
50 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 5, 2013 · Synced Oct 29, 2026, 6:39 PM EDT
Terminated Phase 3 Interventional Results available

BAX 802 in CHA With Inhibitors

NCT02895945
View directory record Official record
Conditions
Hemophilia A
Interventions
Antihemophilic Factor (Recombinant), Porcine Sequence (BAX 802)
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
12 Years to 75 Years · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
3
States / cities
Peoria, Illinois • Winston-Salem, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 20, 2021 · Synced Oct 29, 2026, 6:39 PM EDT
Completed Phase 1 Interventional Results available

BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies

NCT02569476
View directory record Official record
Conditions
B-cell Lymphoid Malignancies
Interventions
Zanubrutinib, Obinutuzumab
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
Fort Myers, Florida • West Palm Beach, Florida • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 26, 2024 · Synced Oct 29, 2026, 6:39 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Motivational Refinements for Facilitating Reinforcement Schedule Thinning

NCT05790668
View directory record Official record
Conditions
Decreasing Destructive Behavior, Increasing Functional Communicative Behavior
Interventions
Traditional Schedule Thinning, PIA-Informed Schedule Thinning, PIA-Informed Schedule Thinning with Competing Stimuli
Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
3 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
2
States / cities
New Brunswick, New Jersey • Somerset, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 29, 2026, 6:39 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia

NCT02604433
View directory record Official record
Conditions
Erythrocyte Transfusion, Beta-Thalassemia
Interventions
Luspatercept, Placebo
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
6
States / cities
Los Angeles, California • Oakland, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 29, 2026, 6:39 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)

NCT03033914
View directory record Official record
Conditions
Hodgkin Lymphoma
Interventions
doxorubicin, Bleomycin, vinblastine, dacarbazine, Nivolumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
9
States / cities
Detroit, Michigan • Basking Ridge, New Jersey • Hackensack, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 29, 2026, 6:39 PM EDT
Completed Phase 1 Interventional

CD19-specific T-cell for Chronic Lymphocytic Leukemia (CLL)

NCT01653717
View directory record Official record
Conditions
Advanced Cancers, Leukemia
Interventions
Leukapheresis, Fludarabine, Cyclophosphamide, T-cell Infusion
Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Oct 29, 2026, 6:39 PM EDT
Enrolling by invitation No phase listed Observational

Biomarker Levels During Indwelling Pleural cAtheter Sample Testing

NCT02092155
View directory record Official record
Conditions
Malignant Pleural Effusions
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 99 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 29, 2026, 6:39 PM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

Oral Penicillin and Penicillin Levels in Venous Umbilical Cord Blood

NCT00823433
View directory record Official record
Conditions
Group B Streptococcus
Interventions
oral penicillin V
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 4, 2016 · Synced Oct 29, 2026, 6:39 PM EDT
Active, not recruiting Not applicable Interventional Results available

Positron Emission Tomography in Women With Advanced HER2-Positive Breast Cancer

NCT01093612
View directory record Official record
Conditions
Breast Cancer, Stage IV Breast Cancer
Interventions
positron emission tomography, copper Cu 64-DOTA-trastuzumab, Biopsy, Immunohistochemistry staining method, laboratory biomarker analysis, mutation analysis
Procedure · Radiation · Other + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 29, 2026, 6:39 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Immunological Responses of COVID-19 Vaccination

NCT05238467
View directory record Official record
Conditions
Cancer; Chemotherapy
Interventions
COVID antibody titers in the blood
Other
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 29, 2026, 6:39 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Good Oral Health - A Bi-level Intervention to Improve Older Adult Oral Health

NCT02419144
View directory record Official record
Conditions
Gingivitis
Interventions
AMI and campaigns
Behavioral
Lead sponsor
UConn Health
Other
Eligibility
18 Years and older
Enrollment
331 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 11, 2021 · Synced Oct 29, 2026, 6:39 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism

NCT00837616
View directory record Official record
Conditions
Turner Syndrome, Hypogonadism, Premature Ovarian Failure
Interventions
17 B estradiol orally, 17 B estradiol
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
13 Years to 20 Years · Female only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
2
States / cities
Jacksonville, Florida • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Oct 29, 2026, 6:39 PM EDT
Completed Not applicable Interventional

Dietary Oxysterols and β-Cell Function Among African Americans

NCT05072587
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Plant-based diet with no oxysterols, Standard ADA Diet (SADA)
Behavioral
Lead sponsor
Morehouse School of Medicine
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 29, 2026, 6:39 PM EDT
Terminated Not applicable Interventional Results available

Feasibility Study of New Method of Diagnostic and Prediction of Painful CIPN

NCT03206216
View directory record Official record
Conditions
Burning Pain, Impaired Balance, Malignant Ovarian Neoplasm, Numbness, Peripheral Neuropathy, Pain, Acute, Tingling
Interventions
Diode Laser fiber type Selective Stimulator (DLss)
Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 29, 2026, 6:39 PM EDT
Terminated Phase 1 Interventional

First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors

NCT04528836
View directory record Official record
Conditions
Tumor, Solid
Interventions
BBP-398 (Formerly known as IACS-15509)
Drug
Lead sponsor
Navire Pharma Inc., a BridgeBio company
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
10
States / cities
Birmingham, Alabama • Duarte, California • La Jolla, California + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Oct 29, 2026, 6:39 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Natural History of Gene Expression in the Lung Cells of Non-Smokers, Smokers and Ex-Smokers in Health and Disease

NCT00974064
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD), Smoking, Smoking Cessation, Chronic Bronchitis, Emphysema
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Oct 29, 2026, 6:39 PM EDT
Active, not recruiting Phase 1 Interventional

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

NCT06257264
View directory record Official record
Conditions
Breast Cancer, Small Cell Lung Cancer, Ovarian Cancer, Gastric Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Advanced Solid Tumor, Endometrial Cancer, Prostate Cancer, TNBC - Triple-Negative Breast Cancer, GastroEsophageal Cancer, Bladder Cancer
Interventions
BG-68501, Fulvestrant, BGB-43395
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
6
States / cities
Newport Beach, California • Lake Mary, Florida • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 29, 2026, 6:39 PM EDT